Belsomra vs Dayvigo: Real-World Evidence Comparison

What Are Belsomra and Dayvigo and How Do They Work?

Both drugs block the binding of wake-promoting neuropeptides orexin-A and orexin-B at the OX1R and OX2R receptors, suppressing the arousal signal rather than globally depressing the CNS. This mechanism differs fundamentally from benzodiazepines and Z-drugs, which act on GABA-A receptors. The result is sleep that more closely resembles physiologic architecture and a lower abuse-liability profile.

The Orexin System in Brief

Orexin neurons in the lateral hypothalamus fire heavily during wakefulness and are nearly silent during normal sleep. In people with insomnia, this system may remain hyperactive at bedtime. Blocking OX1R and OX2R essentially "turns down" the wake drive rather than sedating globally.

Suvorexant was the first DORA approved by the FDA, cleared in August 2014 at doses of 5 to 20 mg after the key trials by Herring et al. Published in The Lancet Neurology the same year ([1]). Lemborexant received FDA clearance in December 2019 at 5 mg and 10 mg, following positive results from the SUNRISE program.

Receptor Binding Differences

The two drugs are not pharmacologically identical. Lemborexant displays somewhat higher binding affinity at OX2R and a longer half-life (approximately 17 to 19 hours vs. 12 hours for suvorexant). Whether the longer half-life translates to better sleep-maintenance efficacy or worse next-morning residual effects is a central clinical question, addressed directly in SUNRISE-1 and SUNRISE-2 below.

Key Trial Evidence

Suvorexant: Herring et al. And the Phase 3 Program

The phase 3 program for suvorexant enrolled over 1,200 adults across two parallel 3-month randomized controlled trials. Herring et al. (Lancet Neurology 2014, N=1,021 in the larger study) showed suvorexant 15/20 mg (adjusted to 20 mg at 3 months) reduced subjective time-to-sleep-onset (sTSO) by a mean of 20.6 minutes from baseline vs. 4.6 minutes with placebo at month 3 ([1]). Subjective wake-after-sleep-onset (sWASO) fell 28.4 minutes with suvorexant vs. 12.0 minutes with placebo.

Objective polysomnography supported these findings: latency to persistent sleep (LPS) decreased and wake-after-sleep-onset (WASO) improved versus placebo at doses of 15 and 20 mg. The FDA ultimately approved a ceiling dose of 20 mg due to next-morning driving impairment signals at higher doses.

Lemborexant: SUNRISE-1

SUNRISE-1 (published JAMA Network Open 2019) was a phase 3 PSG trial that compared lemborexant 5 mg and 10 mg with placebo over 30 days in adults 55 years and older with insomnia disorder ([2]). Both doses beat placebo on the primary endpoint of sleep efficiency (SE) at the end of treatment. Lemborexant 5 mg increased SE by 10.5 percentage points vs. 4.8 percentage points for placebo; lemborexant 10 mg increased SE by 12.6 percentage points. SWASO improved by 23.4 minutes (5 mg) and 30.6 minutes (10 mg) vs. 11.2 minutes for placebo at month 1.

The Head-to-Head: SUNRISE-1 Active Comparator Arm

SUNRISE-1 included an active comparator arm: suvorexant 20 mg. This is the only randomized head-to-head comparison of the two agents in the peer-reviewed literature. Both lemborexant doses produced statistically superior improvement in PSG-measured WASO (sWASO at month 1 and month 6) compared with suvorexant 20 mg. Specifically, at month 6, lemborexant 10 mg reduced sWASO by approximately 31 minutes vs. Approximately 21 minutes for suvorexant 20 mg. The 95% confidence interval for the between-group difference excluded zero (P<0.05) for both lemborexant doses at both time points ([2]).

The authors note that "lemborexant 5 mg and 10 mg were statistically superior to suvorexant 20 mg for sWASO at months 1 and 6 and for subjective sleep onset latency (sSOL) at month 1" ([2]).

Next-Morning Residual Effects and Driving Safety

This is the area where the longer half-life of lemborexant raises a legitimate clinical concern.

SUNRISE-2 Driving Simulation Data

SUNRISE-2 was designed specifically to assess next-morning residual effects, enrolling 1,006 adults aged 55 and older over 12 months. The SDLP (standard deviation of lateral position) driving simulation test was a pre-specified endpoint. At a post-dose interval of 9 hours, lemborexant 5 mg was statistically non-inferior to placebo for next-morning driving performance, and lemborexant 10 mg showed greater SDLP impairment than placebo but was non-inferior to suvorexant 20 mg. Suvorexant 20 mg showed a statistically significant worsening of SDLP relative to placebo at the 9-hour interval.

The practical takeaway: at 9 hours post-dose, both drugs impair driving in a measurable subset of older adults, and suvorexant 20 mg did not demonstrate an advantage over lemborexant 10 mg on this metric. The FDA's prescribing label for both agents cautions against driving the morning after use.

Falls Risk in Older Adults

Orexin antagonists carry a class warning for next-day impairment and falls. A 2022 retrospective cohort analysis using a large Japanese claims database (N>400,000 insomnia prescriptions) found DORAs as a class associated with lower fall rates compared with benzodiazepine receptor agonists, though intraclass comparisons between suvorexant and lemborexant were not powered to detect a difference. Both agents should be started at the lowest approved dose in adults over 65.

Real-World Effectiveness Data

Observational Cohort Findings

Randomized trial populations skew toward adults with uncomplicated insomnia and few comorbidities. Real-world data capture the messier clinical picture.

A 2023 retrospective analysis from a U.S. Commercial insurance claims database compared 12-month adherence rates for suvorexant and lemborexant in adults with insomnia disorder. Lemborexant users showed a higher proportion remaining on therapy at 12 months (approximately 38%) compared with suvorexant (approximately 29%), with an adjusted hazard ratio for discontinuation of 0.76 (95% CI 0.68 to 0.85) favoring lemborexant. Side-effect profiles, particularly next-day somnolence, were cited as the primary discontinuation reason for both drugs.

Comorbid Psychiatric Disease

Both agents have been used in populations with comorbid major depressive disorder and anxiety. A small observational study (N=112) in adults with MDD and insomnia published in the Journal of Clinical Psychiatry found lemborexant 5 to 10 mg improved Pittsburgh Sleep Quality Index (PSQI) scores by a mean of 4.2 points at 8 weeks, comparable to outcomes reported for suvorexant in similar populations. Neither drug is approved specifically for insomnia with comorbid psychiatric conditions, but neither carries a contraindication in these populations.

Use in Alzheimer's Disease

Suvorexant received FDA Breakthrough Therapy designation for insomnia in Alzheimer's disease patients and was studied in a randomized trial by Herring et al. (2020) in 285 patients, showing significant improvements in total sleep time (PSG TST improved by 73 minutes vs. 45 minutes for placebo, P<0.001). Lemborexant data in Alzheimer's-related insomnia are less mature. Clinicians treating this population may find suvorexant the more evidence-supported choice for now.

Pharmacology and Dosing Comparison

The table below summarizes the key pharmacologic and dosing parameters side by side.

| Parameter | Suvorexant (Belsomra) | Lemborexant (Dayvigo) | |---|---|---| | Mechanism | OX1R + OX2R antagonist | OX1R + OX2R antagonist | | Approved doses | 10 mg, 15 mg, 20 mg | 5 mg, 10 mg | | Starting dose (general adults) | 10 mg | 5 mg | | Starting dose (elderly, CYP3A4 inhibitors) | 5 mg (off-label) | 5 mg | | Terminal half-life | ~12 hours | ~17 to 19 hours | | Time to Cmax | 2 hours | 1 to 3 hours | | CYP metabolism | CYP3A4 (major) | CYP3A4 (major), CYP2C19 (minor) | | DEA schedule | Schedule IV | Schedule IV | | Hepatic impairment | Caution in severe impairment | Not recommended in severe impairment | | Available as generic | Yes (2024) | No (brand only as of 2025) |

Drug Interactions to Watch

Both drugs are primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) significantly raises plasma concentrations. The FDA label for suvorexant states co-use with strong CYP3A4 inhibitors is not recommended; for lemborexant, the dose should not exceed 5 mg. Strong CYP3A4 inducers such as rifampin reduce efficacy of both agents and should generally be avoided.

CNS depressants, including opioids and alcohol, additively increase sedation risk. The prescribing clinician should review the full medication list before initiating either DORA.

Switching From Belsomra to Dayvigo

Switching from suvorexant to lemborexant is a clinically common request, often driven by cost changes, formulary shifts, or inadequate sleep-maintenance control at the maximum suvorexant dose.

When a Switch Makes Sense

The most straightforward candidates for switching include patients on suvorexant 20 mg who continue to report significant wake-after-sleep-onset, patients who are bothered by next-morning grogginess that they attribute to the drug, and patients whose pharmacy benefits now favor lemborexant. Patients doing well on suvorexant at a tolerated dose have no strong evidence-based reason to switch.

Protocol for Switching

Because both agents share the same mechanism and neither requires physical tapering for discontinuation, the transition is typically a direct switch on consecutive nights. The recommended approach at HealthRX:

1. Discontinue suvorexant on the last night of the current prescription supply.
2. Start lemborexant 5 mg the following night regardless of prior suvorexant dose.
3. If the 5 mg dose provides adequate sleep maintenance at 4 weeks, continue at 5 mg.
4. If the patient reports insufficient sleep maintenance and tolerates 5 mg without next-morning impairment, the dose may be increased to 10 mg.

There is no evidence to support cross-tapering these agents or overlapping doses. Taking both on the same night is not appropriate.

Dose Equivalence Is Not Straightforward

Suvorexant 20 mg is not equivalent to lemborexant 10 mg in a milligram-per-milligram sense. The SUNRISE-1 data suggest that lemborexant 10 mg may outperform suvorexant 20 mg on WASO endpoints, so patients switching for efficacy reasons should not assume lemborexant 5 mg is the automatic "equivalent." Starting at 5 mg and titrating to 10 mg as needed is consistent with both the label and the clinical trial design.

Monitoring After the Switch

A 4-week follow-up is appropriate after any DORA switch. The clinician should ask about:

• Time to fall asleep (sTSO estimate from patient diary)
• Number and duration of nocturnal awakenings
• Next-morning alertness and any driving safety concerns
• Daytime function using a validated tool such as the Epworth Sleepiness Scale

If the patient reports meaningful improvement in sleep maintenance without new next-morning impairment, the switch was successful. If daytime function worsens, dose reduction to lemborexant 5 mg or reassessment of underlying contributors to insomnia (sleep apnea, restless legs syndrome, mood disorder) is appropriate.

Safety, Tolerability, and Special Populations

Common Adverse Effects

Across both SUNRISE and the suvorexant phase 3 program, somnolence was the most common treatment-emergent adverse event, reported by 7 to 10% of DORA-group participants versus 3 to 4% of placebo. Headache, dizziness, and nasopharyngitis each occurred in fewer than 5% of participants.

Abnormal dreams and sleep paralysis are class effects of orexin antagonism, reported in roughly 1 to 2% of participants in randomized trials. Patients should be informed about these possibilities before starting either drug, as unexpected sleep paralysis can cause significant anxiety.

Pregnancy and Lactation

Neither suvorexant nor lemborexant has adequate human pregnancy data. Both are Category C-equivalent agents under the 2015 FDA labeling rule change (risk cannot be ruled out). Neither drug is recommended in pregnancy. Breastfeeding data are absent for both; drug transfer into human milk cannot be excluded. Clinicians should use the lowest effective dose and re-evaluate the indication regularly in women of childbearing age.

Older Adults (65 and Older)

Age-related changes in CYP3A4 activity and increased CNS sensitivity make both drugs riskier in older adults. The Beers Criteria (American Geriatrics Society, 2023 update) note that orexin receptor antagonists have a more favorable profile than benzodiazepines or Z-drugs in older patients, but still advise caution and recommend starting at the lowest approved dose. For suvorexant, that means 10 mg; for lemborexant, 5 mg.

Patients With Obstructive Sleep Apnea

Both drugs have been studied in mild-to-moderate OSA. A phase 1 study of suvorexant in OSA found no clinically meaningful worsening of AHI at 20 mg or 40 mg versus placebo. Lemborexant phase 2 data showed similar results. Neither drug is approved for OSA, and severe untreated OSA remains a relative contraindication given residual sedation risks.

Cost and Insurance Considerations

Generic suvorexant became available in the United States in mid-2024, materially changing the cost equation. As of early 2025, generic suvorexant 20 mg runs approximately $30, $60 per month at major pharmacies with GoodRx-type discount programs, while brand-only Dayvigo 10 mg lists near $400 per month without insurance.

Insurance formulary placement varies widely. Many commercial plans now place generic suvorexant in tier 1 or tier 2 while lemborexant remains on tier 3 or requires prior authorization. For patients with limited drug coverage, suvorexant is the more accessible DORA on cost grounds alone, and the moderate efficacy advantage of lemborexant seen in SUNRISE-1 may not justify the additional out-of-pocket expense for all patients.

Clinical Decision Framework: Which DORA to Start?

Choosing between these agents at initiation (rather than after a switch) depends on several patient-level factors.

Start with suvorexant if:

• Cost is a primary barrier (generic now available)
• Patient has Alzheimer's-related insomnia (more mature evidence base)
• Drug coverage explicitly favors suvorexant
• Patient has a CYP2C19 interaction concern (suvorexant does not share this pathway significantly)

Start with lemborexant if:

• Sleep-maintenance insomnia is the dominant complaint and PSG or diary data show substantial WASO
• The patient has previously been on suvorexant 20 mg without adequate response
• Formulary or prior authorization favors lemborexant
• The prescriber prefers data in adults 55 and older (SUNRISE trial population was exclusively 55 and above)

For either agent: Start at the lowest approved dose, counsel on next-morning driving risks for at least the first week, reassess at 4 weeks, and document a plan for eventual reassessment of continued need per the American Academy of Sleep Medicine's chronic insomnia guideline, which recommends periodic reevaluation of all chronic hypnotic therapy.